Renal Cell Carcinoma

P2, N=15, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Nov 2026

P2, N=160, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

P2, N=10, Terminated, M.D. Anderson Cancer Center | Trial completion date: Jul 2027 --> Nov 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2027 --> Nov 2025; The study met its prespecified futility criteria during the prespecified interim futility analysis after enrolling the first cohort of 10 patients.

This comprehensive analysis demonstrates the superior efficacy of ICI in younger aRCC patients across multiple cohorts, supporting the development of age-stratified therapeutic approaches. Age-dependent expression of TNFSF15 suggests potential molecular mechanisms underlying differential treatment responses.

Here, we synthesize insights from these approaches to define diverse CD8+ T-cell subsets and exhaustion trajectories, as well as the origins, phenotypic diversity, and functional states of other immune cells including tumor-associated macrophages, dendritic cells, natural killer cells and cancer-associated fibroblasts. Together, these findings highlight the transformative potential of single-cell technologies to unravel TME complexity, identify biomarkers of therapeutic response, and guide precision immunotherapy in RCC.

This study investigated the renoprotective action of linagliptin compared to doxorubicin against thioacetamide (TAA) and diethyl nitrosamine (DEN)-induced renocarcinogenesis in a rat model. These findings demonstrate that linagliptin, especially at 6 mg/kg/day, exhibits significant renoprotective activities through multifarious mechanisms involving antioxidant action and regulation of key molecular pathways. The present study presents evidence for the potential therapeutic application of linagliptin in renal manifestations of renocarcinogenesis.

Regarding therapeutic aspects, we discovered that DNA methyltransferase inhibitors serve as potential MAOB inducer in ccRCC. The current findings reveal novel mechanisms by which MAOB suppresses the malignancy of ccRCC and suggest that MAOB may serve as a valuable prognostic marker in the management of ccRCC.

We herein describe a 67-year old male with bilateral synchronous masses treated with open bilateral adrenal sparing radical nephrectomy. His final pathology was interestingly found to have novel, differing aggressive cancers: a TFE3-rearranged RCC and a grade 4 WHO clear cell RCC.

This study presents a novel and effective strategy to induce the abscopal effect through a synergistic combination of targeted drug delivery, radiotherapy, and immunotherapy. The approach offers strong translational potential for improving radioimmunotherapy outcomes in renal and potentially other immunogenic cancers.

P=N/A, N=40, Recruiting, NYU Langone Health | Trial completion date: Jun 2025 --> Sep 2026 | Trial primary completion date: Feb 2025 --> Jun 2026

This review consolidates existing evidence and suggests that mixed cancer syndromes, especially LFS, LS, and HBOC but also pathogenic ATM and CHEK2 variants may predispose individuals to skin cancers, warranting tailored screening and preventive measures. On the basis of emerging evidence, we recommend dermatologic evaluation and individualized UV protection strategies for patients with reviewed hereditary cancer syndromes to reduce skin cancer risk and enhance early detection.

EVT is a rare renal tumor entity with characteristic imaging features, though its imaging presentation may vary depending on the underlying pathology. Accurate identification of EVT will contribute to improving the classification and diagnosis of renal tumors.